Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.

Literature DB >> 29653607

The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.

David S Knopman¹, Samantha Budd Haeberlein², Maria C Carrillo³, James A Hendrix⁴, Geoff Kerchner⁵, Richard Margolin⁶, Paul Maruff⁷, David S Miller⁸, Gary Tong⁹, Maria B Tome¹⁰, Melissa E Murray¹¹, Peter T Nelson¹², Mary Sano¹³, Niklas Mattsson¹⁴, David L Sultzer¹⁵, Thomas J Montine¹⁶, Clifford R Jack¹, Hartmuth Kolb¹⁷, Ronald C Petersen¹, Prashanthi Vemuri¹, Megan Zoschg Canniere¹⁸, Julie A Schneider¹⁹, Susan M Resnick²⁰, Gary Romano²¹, Argonde Corien van Harten²², David A Wolk²³, Lisa J Bain²⁴, Eric Siemers²⁵.

Abstract

The Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the "A, T, N System" (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.

Entities: Chemical Disease Gene Species

Keywords: Alzheimer's disease; Amyloid; Biomarkers; Clinical trials; Neurodegeneration; Tau

Mesh：

Substances：
Biomarkers

Year: 2018 PMID： 29653607 PMCID： PMC6747694 DOI： 10.1016/j.jalz.2018.03.002

Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566

83 in total

1. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors: Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566

2. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors: Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566

3. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

Authors: Fiona M Clement; Anthony Harris; Jing Jing Li; Karen Yong; Karen M Lee; Braden J Manns
Journal: JAMA Date: 2009-10-07 Impact factor: 56.272

4. The stress and psychological morbidity of the Alzheimer patient caregiver.

Authors: M T González-Salvador; C Arango; C G Lyketsos; A C Barba
Journal: Int J Geriatr Psychiatry Date: 1999-09 Impact factor: 3.485

5. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort.

Authors: J A Luchsinger; M X Tang; Y Stern; S Shea; R Mayeux
Journal: Am J Epidemiol Date: 2001-10-01 Impact factor: 4.897

Review 6. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship.

Authors: Peter T Nelson; Heiko Braak; William R Markesbery
Journal: J Neuropathol Exp Neurol Date: 2009-01 Impact factor: 3.685

7. Relationships between biomarkers in aging and dementia.

Authors: W J Jagust; S M Landau; L M Shaw; J Q Trojanowski; R A Koeppe; E M Reiman; N L Foster; R C Petersen; M W Weiner; J C Price; C A Mathis
Journal: Neurology Date: 2009-10-13 Impact factor: 9.910

Review 8. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

Authors: Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal: Lancet Neurol Date: 2007-08 Impact factor: 44.182

9. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons.

Authors: Peter T Nelson; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Charles D Smith; Daron G Davis; John W Poduska; Ela Patel; Marta S Mendiondo; William R Markesbery
Journal: Brain Pathol Date: 2008-11-19 Impact factor: 6.508

10. Revising the definition of Alzheimer's disease: a new lexicon.

Authors: Bruno Dubois; Howard H Feldman; Claudia Jacova; Jeffrey L Cummings; Steven T Dekosky; Pascale Barberger-Gateau; André Delacourte; Giovanni Frisoni; Nick C Fox; Douglas Galasko; Serge Gauthier; Harald Hampel; Gregory A Jicha; Kenichi Meguro; John O'Brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Marie Sarazin; Leonardo C de Souza; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal: Lancet Neurol Date: 2010-10-09 Impact factor: 44.182

31 in total

1. Multi-faceted therapeutic strategy for treatment of Alzheimer's disease by concurrent administration of etodolac and α-tocopherol.

Authors: Khaled H Elfakhri; Ihab M Abdallah; Andrew D Brannen; Amal Kaddoumi
Journal: Neurobiol Dis Date: 2019-01-30 Impact factor: 5.996

2. Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Authors: Tessandra Stewart; Min Shi; Aanchal Mehrotra; Patrick Aro; David Soltys; Kathleen F Kerr; Cyrus P Zabetian; Elaine R Peskind; Peggy Taylor; Leslie M Shaw; John Q Trojanowski; Jing Zhang
Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472

3. Computing Univariate Neurodegenerative Biomarkers with Volumetric Optimal Transportation: A Pilot Study.

Authors: Yanshuai Tu; Liang Mi; Wen Zhang; Haomeng Zhang; Junwei Zhang; Yonghui Fan; Dhruman Goradia; Kewei Chen; Richard J Caselli; Eric M Reiman; Xianfeng Gu; Yalin Wang
Journal: Neuroinformatics Date: 2020-10

4. The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Authors: Michael S Rafii; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Florence Lai; H Diana Rosas; Shahid Zaman; Melissa E Petersen; Andre Strydom; Juan Fortea; Benjamin Handen; Sid O'Bryant
Journal: Alzheimers Dement (Amst) Date: 2020-10-27

Review 5. Acute versus Chronic Exposures to Inhaled Particulate Matter and Neurocognitive Dysfunction: Pathways to Alzheimer's Disease or a Related Dementia.

Authors: Minos Kritikos; Samuel E Gandy; Jaymie R Meliker; Benjamin J Luft; Sean A P Clouston
Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472

Review 6. Cerebral Amyloid Angiopathy, Alzheimer's Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets.

Authors: J Weldon Furr; Diego Morales-Scheihing; Bharti Manwani; Juneyoung Lee; Louise D McCullough
Journal: Neuromolecular Med Date: 2019-10-04 Impact factor: 3.843